Quinazoline tyrosine kinase inhibitors of EGFR have been shown to induce inactive EGFR homodimers and EGFR/HER2 heterodimers in EGFR over-expressing cancer cells [36] as well as decreasing EGFR/HER3 mediated PI3K/Akt pathway [11]. This evidence concerns the gene AKT1 and cancer.